阿普米司特治疗儿童皮肤病——全面综述
Apremilast in Paediatric Dermatoses - A Comprehensive Review.
作者信息
Patro Nibedita, Panda Maitreyee, Dash Mrityunjay, Das Anupam
机构信息
Department of Skin and VD, Hi-Tech Medical College and Hospital, Utkal University, Bhubaneswar, Odisha, India.
Department of Skin and VD, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India.
出版信息
Indian J Dermatol. 2022 Mar-Apr;67(2):206. doi: 10.4103/ijd.ijd_482_21.
Abstract
Apremilast has recently garnered attention in the management of multiple dermatological conditions including psoriasis. The comparable effectiveness with immunosuppressive drugs and a favorable side effect profile makes the drug, a prudent alternative for managing a gamut of dermatoses. In this article, we have reviewed the literature on apremilast use in children.
摘要
阿普米拉斯最近在包括银屑病在内的多种皮肤病管理中受到关注。与免疫抑制药物相当的疗效以及良好的副作用谱使该药物成为治疗多种皮肤病的明智选择。在本文中，我们回顾了有关阿普米拉斯在儿童中应用的文献。
相似文献
1
Apremilast in Paediatric Dermatoses - A Comprehensive Review.
Indian J Dermatol. 2022 Mar-Apr;67(2):206. doi: 10.4103/ijd.ijd_482_21.
2
On- and Off-Label Uses of Apremilast in Dermatology.
Acta Dermatovenerol Croat. 2020 Dec;28(3):171-179.
3
Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
Clin Cosmet Investig Dermatol. 2022 Mar 8;15:395-402. doi: 10.2147/CCID.S266036. eCollection 2022.
4
The Use of Apremilast in Psoriasis: A Delphi Study.
Actas Dermosifiliogr (Engl Ed). 2020 Mar;111(2):115-134. doi: 10.1016/j.ad.2019.07.005. Epub 2019 Dec 19.
5
Apremilast in dermatology: A review of literature.
Dermatol Ther. 2020 Nov;33(6):e14261. doi: 10.1111/dth.14261. Epub 2020 Sep 27.
6
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat. 2020 Mar;31(2):131-140. doi: 10.1080/09546634.2019.1589641. Epub 2019 Apr 2.
7
Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review.
J Dermatolog Treat. 2022 Feb;33(1):94-99. doi: 10.1080/09546634.2020.1770176. Epub 2020 May 25.
8
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
J Am Acad Dermatol. 2020 Feb;82(2):389-397. doi: 10.1016/j.jaad.2019.08.019. Epub 2019 Aug 10.
9
Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Am J Clin Dermatol. 2021 May;22(3):415-423. doi: 10.1007/s40257-021-00596-6. Epub 2021 Mar 12.
10
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):403-410. doi: 10.1111/jdv.14647. Epub 2017 Nov 15.
本文引用的文献
1
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
Psoriasis (Auckl). 2021 Aug 14;11:109-122. doi: 10.2147/PTT.S320810. eCollection 2021.
2
Apremilast in dermatology: A review of literature.
Dermatol Ther. 2020 Nov;33(6):e14261. doi: 10.1111/dth.14261. Epub 2020 Sep 27.
3
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Dermatol Ther. 2020 Nov;33(6):e13961. doi: 10.1111/dth.13961. Epub 2020 Jul 27.
4
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e676-e679. doi: 10.1111/jdv.16761. Epub 2020 Jul 9.
5
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
Dermatol Ther. 2020 Jul;33(4):e13722. doi: 10.1111/dth.13722. Epub 2020 Jun 24.
6
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
Dermatol Ther. 2020 Jul;33(4):e13668. doi: 10.1111/dth.13668. Epub 2020 Jun 24.
7
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Dermatol Ther. 2020 Jul;33(4):e13618. doi: 10.1111/dth.13618. Epub 2020 Jun 4.
8
Steroid-resistant alopecia totalis in a child successfully treated with oral apremilast and platelet-rich plasma therapy.
Dermatol Ther. 2019 Nov;32(6):e13082. doi: 10.1111/dth.13082. Epub 2019 Sep 30.
9
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
J Am Acad Dermatol. 2020 Feb;82(2):389-397. doi: 10.1016/j.jaad.2019.08.019. Epub 2019 Aug 10.
10
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat. 2020 Mar;31(2):131-140. doi: 10.1080/09546634.2019.1589641. Epub 2019 Apr 2.
Zotero 插件